Salvage Therapy with Bevacizumab–Sunitinib Combination after Failure of Sunitinib Alone for Metastatic Renal Cell Carcinoma: A Case Series

Abstract

Seven patients withmetastatic renal cell carcinoma (mRCC) who had disease progression after treatment with sunitinib monotherapy were treated with salvage therapy of bevacizumab plus sunitinib beginning between June 2006 and May 2007 in an experimental setting at the Georges Pompidou European Hospital in Paris, France. Patients were offered combination therapy in place of best supportive care because no other treatments or entry into clinical trials were possible. Only patients with an absolute neutrophil count of>1500/mm3, a platelet count of>100 000/mm3, a Article info Article history